Literature DB >> 34564790

A digest from evidence-based clinical practice guideline for IgA nephropathy 2020.

Hitoshi Suzuki1, Masao Kikuchi2, Kentaro Koike3, Hiroyuki Komatsu4, Keiichi Matsuzaki5, Kazuo Takahashi6, Daisuke Ichikawa7, Masahiro Okabe3, Yoko Obata8, Ritsuko Katafuchi9, Masao Kihara1, Kaori Kohatsu7, Takaya Sasaki3, Akihiro Shimizu3, Koichi Nakanishi10, Akihiro Fukuda11, Yoichi Miyazaki3, Masahiro Muto1, Hiroyuki Yanagawa1, Yusuke Suzuki1, Shoichi Fujimoto12, Kengo Furuichi13, Hirokazu Okada14, Ichiei Narita15.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34564790     DOI： 10.1007/s10157-021-02095-8

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN： 1342-1751            Impact factor:   2.801


× No keyword cloud information.
  4 in total

1.  Efficacy and safety of leflunomide combined with corticosteroids for the treatment of IgA nephropathy: a Meta-analysis of randomized controlled trials.

Authors:  Guangxin Lv; Chengyuan Ming
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

2.  Protocol for a Phase 1, Open-Label, Multiple-Center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 in the Treatment of Immunoglobulin A Nephropathy.

Authors:  Akihito Tanaka; Kazuhiro Furuhashi; Kumiko Fujieda; Kayaho Maeda; Shoji Saito; Tetsushi Mimura; Yosuke Saka; Tomohiko Naruse; Takuji Ishimoto; Tomoki Kosugi; Fumie Kinoshita; Yachiyo Kuwatsuka; Shinobu Shimizu; Yasuhiro Nakai; Shoichi Maruyama
Journal:  Front Med (Lausanne)       Date:  2022-05-27

Review 3.  Treatment strategy with multidrug therapy and tonsillectomy pulse therapy for childhood-onset severe IgA nephropathy.

Authors:  Yukihiko Kawasaki
Journal:  Clin Exp Nephrol       Date:  2022-02-04       Impact factor: 2.801

4.  A novel COL4A5 splicing variant causing X-linked Alport syndrome: A case report.

Authors:  Naonori Kumagai; Yuji Matsumoto; Tomomi Kondoh; Yohei Ikezumi
Journal:  Hum Genome Var       Date:  2022-08-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.